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Epoxyeicosatrienoic acids (EETs) contribute to blood pressure regulation leading to the
concept that EETs can be therapeutically targeted for hypertension and the associated
end organ damage. In the present study, we investigated anti-hypertensive and kidney
protective actions of an EET analog, EET-B in angiotensin II (ANG II)-induced hypertension.
EET-B was administered in drinking water for 14 days (10 mg/kg/d) and resulted in a
decreased blood pressure elevation in ANG II hypertension. At the end of the two-week
period, blood pressure was 30 mmHg lower in EET analog-treated ANG II hypertensive
rats. The vasodilation of mesenteric resistance arteries to acetylcholine was impaired in
ANG II hypertension; however, it was improved with EET-B treatment. Further, EET-B
protected the kidney in ANG II hypertension as evidenced by a marked 90% decrease in
albuminuria and 54%decrease in nephrinuria. Kidney histology demonstrated a decrease in
renal tubular cast formation in EET analog-treated hypertensive rats. InANG II hypertension,
EET-B treatment markedly lowered renal inﬂammation. Urinary monocyte chemoattractant
protein-1 excretionwas decreased by 55% and kidneymacrophage inﬁltrationwas reduced
by 52% with EET-B treatment. Overall, our results demonstrate that EET-B has anti-
hypertensive properties, improves vascular function, and decreases renal inﬂammation
and injury in ANG II hypertension.
Keywords: epoxyeicosatrienoic acid analog, mesenteric artery, endothelial function, renal inflammation,
angiotensin II
INTRODUCTION
Cytochrome P450 epoxygenase metabolites of arachidonic acid,
epoxyeicosatrienoic acids (EETs), have numerous cardiovascular
and renal actions that make them therapeutically promising in
cardiovascular and renal diseases (Imig, 2008, 2010, 2012; Imig
and Hammock, 2009; Sudhahar et al., 2010). Accordingly, inhibi-
tion of soluble epoxide hydrolase (sEH), which hydrolyzes EETs to
their less biologically active dihydroxyeicosatrienoic acid metabo-
lites, increases EETs bioavailability and exhibited therapeutically
important cardiovascular effects (Imig et al., 2002, 2005; Imig and
Hammock, 2009; Imig, 2010, 2012).
In line with the observations that increased EET bioavailabil-
ity by sEH inhibition provides beneﬁcial cardiovascular and renal
effects, several sEH inhibitors have been developed and tested
for anti-hypertensive effects in multiple models of hypertension
including angiotensin (ANG II)-dependent hypertension (Imig
et al., 2002, 2005; Zhao et al., 2004; Loch et al., 2007; Manhiani
et al., 2009). Apart from sEH inhibitors, one relevant approach to
therapeutically targeting EETs for cardiovascular diseases would
be the development of agonist analogs for EETs. This is an impor-
tant approach as biological effects of EETs are limited by solubility
and storage issues (Falck et al., 2003). EET analogs are designed
to resist metabolism and improve solubility (Yang et al., 2007;
Falck et al., 2009). Moreover, several earlier studies demonstrated
that these EET analogs vasodilate coronary, renal, and mesenteric
arteries (Imig et al., 1999; Gauthier et al., 2004; Dimitropoulou
et al., 2007). Considering the promising vascular actions of early
generation EET analogs, it was important to develop orally active
EET analogs, which can eventually be developed as novel cardio-
vascular therapeutic agents. Indeed, a number of experimental
studies support the use of EET analogs in cardiovascular disease.
An EET analog, NUDSA, dilated renal afferent arterioles, reduced
blood pressure in hypertensive rats and mice, improved insulin
sensitivity in metabolic syndrome mice, and decreased experi-
mental cardiac reperfusion injury (Seubert et al., 2007; Sodhi et al.,
2009; Imig et al., 2010).
More recently, newer generations of EET analogs have been
developed and are beginning to demonstrate therapeutic potential
when administered in vivo either acutely or chronically. We have
developed a series of orally active EET analogs and demonstrated
their anti-hypertensive and organ protective effects in a number of
pathologies (Hye Khan et al., 2013, 2014). In the present study, we
investigated the anti-hypertensive effect of one such EET analog,
EET-B, synthesized by replacing the COOH group at carbon 1 of
the EETpharmacophorewith a heterocyclic surrogate.Wedemon-
strate anti-hypertensive and kidney protective effects of this EET
analog in ANG II induced hypertension.
MATERIALS AND METHODS
CHEMICALS
All chemicals were purchased from Sigma-Aldrich (Ann Arbor,
MI, USA). The EET analog, EET-B [(N-(5-((2-acetamidobenzo
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[d]thiazol-4-yl)oxy) pentyl)-N-isopropylheptanamide)] was
designed, synthesized, and analyzed for purity in the laboratory of
John R. Falck. The structure of EET-B is described in Figure 1.
ANIMALS
Male Sprague-Dawley (SD) rats weighing between 225 and 275 g
(n = 6–8/group) and purchased from Charles River Laborato-
ries were used in this study. Animal protocols were in accordance
with National Institutes of Health guidelines and approved by the
Institutional Animal Care and Use Committees. Animals were fed
normal rat chow throughout the experiment and were housed
under conditions of constant temperature and humidity with a
12:12 h light–dark cycle. Rats were allowed to acclimatize to these
conditions for 7 days before starting any experimental protocol.
TELEMETRY BLOOD PRESSURE MEASUREMENT
In order to measure blood pressure, telemetry transmitters (Data
Sciences Inc., Saint Paul, MN, USA) were implanted 2 weeks prior
to the experiment in rats under isoﬂurane anesthesia. A subcuta-
neous pocket between the caudal edge of the ﬂank and the most
cranial extension of the knee’s range of motion was made. The
transmitter body was placed in the subcutaneous pocket with the
tissue snug. The transmitter catheter inserted into femoral artery
and advanced to the abdominal aorta. The incisionwas closedwith
sutures and sealedwith sterile tissue adhesive to help prevent infec-
tion. The suture was removed 7 days later after the incision had
completely healed. Rats were allowed to recover from surgery and
were returned to individual housing. A baseline arterial pressure
was recorded for 3–5 days prior to the experimental period. Blood
pressure and heart rate were continuously recorded throughout
the experimental period.
FIGURE 1 | Structure of EET-B [(N -(5-((2-acetamidobenzo[d]thiazol-
4-yl)oxy) pentyl)-N -isopropylheptanamide)].
ANTI-HYPERTENSIVE EFFECTS OF EET-B IN ANG II-HYPERTENSIVE
RATS
This experiment was carried out in a set of rats implanted with
an ANG II ﬁlled ALZET® mini-osmotic pumps (s.c.) to deliver
ANG II at a dose of 60 ng/min for 14 days and blood pressure
monitored by telemetry transmitter. On the ﬁrst day of ANG II
pump implantation, EET-B treatment in drinking water ad libi-
tum was started and continued for 14 days while blood pressure
and heart rate were monitored. EET-B, administered in drinking
water (10 mg/kg/day), was prepared with 1% PEG-400 and 0.05%
ethanol. The vehicle-treated groups received drinking water con-
taining 1% PEG-400 and 0.05% ethanol ad libitum and blood
pressure and heart rate were monitored.
VASCULAR REACTIVITY STUDIES
Second order mesenteric resistance arteries were collected at the
end of the experimental protocol to determine vascular function.
Arterial segments were mounted between two glass cannulas in a
pressure myograph system (Danish Myo Technology model 111P,
DMT, Aarhus, Denmark). Mesenteric arteries were oxygenated in
95% O2/5% CO2 Krebs physiological salt solution at pH 7.4 and
37◦C. Under no-ﬂow conditions, the pressure within the vessel
was increased in 10-mmHg increments from 20 to 65 mmHg. The
blood vessel was then equilibrated at 65 mmHg for 30 min and
control lumen diameter was calculated as the mean diameter dur-
ing the last minute of the 30-min equilibration period. Mesenteric
resistance arteries were constrictedwith the thromboxanemimetic
U-46619 and diameter of the constricted artery was calculated as
the mean during the last minute of the 15 min period. Following
U46619 constriction, vessel diameter responses to graded con-
centrations of acetylcholine (0.001–10 μM) were assessed. The
nitric oxide donor, sodium nitroprusside (100 μM) was added to
the bath at the end of the experimental period to ensure vascular
integrity. Relaxation responses were plotted as a percent relaxation
from maximum contraction.
BIOCHEMICAL MEASUREMENTS
Urinary biochemical analysis was done using commercially avail-
able ELISA assay kits; albumin and nephrin from Exocell
(Philadelphia, PA, USA), and monocyte chemoattractant protein-
1 (MCP-1) from BD Biosciences (San Jose, CA, USA). Urinary
sodium was measured using ISE (Ion Selective Electrode) based
method (EasyLyte Analyzer, Medica Corporation, Bedford, MA,
USA).
KIDNEY HISTOLOGY
For histological analysis, kidneys were excised, longitudinally sec-
tioned, immersion-ﬁxed in 10% neutral buffered formalin and
parafﬁn-embedded. The kidney sections were embedded and
cut into 4 μm slices for use in histology protocols. Formalin-
ﬁxed parafﬁn-embedded kidney slices were de-parafﬁnized, re-
hydrated and stained with Periodic Acid-Schiff (PAS) reagents.
Two observers in a blinded design conducted histological analysis
of tubular casts in the PAS stained slides at a magniﬁcation of 200x
using Nikon NIS Elements Software. The percentage area positive
for cast was calculated from the mean of 10 ﬁelds (200x) for each
animal.
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IMMUNOHISTOPATHOLOGICAL ANALYSIS
Formalin-ﬁxed and parafﬁn-embedded kidney slices were de-
parafﬁnized, re-hydrated, and subjected to immunohistochem-
istry protocol. Kidney sections were immunostained with
anti-CD68 (1:50; Serotec, Raleigh, NC, USA) to determine
macrophage/monocyte inﬁltration. Biotinylated donkey anti-
mouse secondary antibody (1:200) was used for development
with avidin-biotinylated HRP complex (Vectastain ABC Elite kit,
Vector Laboratories, Burlingame, CA, USA) followed by counter-
staining with hematoxylin and mounted. Stained sections were
visualized by light microscopy at 400x magniﬁcation and digital
images of the stained kidney sections were taken for analysis using
Nikon NIS Elements Software (Nikon Instruments Inc., Melville,
NY, USA). Macrophage/monocyte inﬁltration was determined by
point counting of CD68-positive cells by two experienced review-
ers in a blinded design. Twenty images were captured for each
kidney section and the number of positive cells per image was
divided by the metric area of the image to obtain the number of
positive cells per mm2.
STATISTICS
Data expressed as mean ± S.E.M. Statistical signiﬁcance between
two measurements was determined by the two-tailed unpaired
Student’s t-test (and among groups it was determined by repeated
measure one-way analysis of variance followed by Tukey’s post
hoc test) using GraphPad Prism®Version 4.0 software (GraphPad
Software Inc, La Jolla, CA, USA). Probability values of P < 0.05
were considered signiﬁcant where the critical value of P was two-
sided.
RESULTS
EET-B REDUCES BLOOD PRESSURE IN ANG II HYPERTENSIVE RATS
As demonstrated in Figure 2, oral administration of EET-B
markedly blunted the development of ANG II hypertension with-
out affecting heart rate. At the end of the 14-day ANG II infusion
FIGURE 2 | Effects of orally administered EET-B on mean arterial
pressure and heart rate in angiotensin II (ANG II) hypertensive rats.
EET-B was administered at a dose of 10 mg/kg/day in the drinking water for
14 days. Blood pressure (A) and heart rate (B) data are presented as the
average of 24 h readings. *P < 0.05 vs. ANG II + Vehicle. All data
presented as mean ± SEM, n = 8/group.
period, mean arterial pressure in vehicle-treated ANG II hyper-
tensive rats averaged 152 ± 4 mmHg. EET-B treated ANG II
hypertensive rats had lower blood pressure at the end of 14-day
period and mean arterial pressure averaged 114 ± 14 mmHg
(P < 0.05; Figure 2A). Heart rate was not different between
vehicle and EET-B treatment in ANG II hypertensive rats. The
heart rate averaged 419 ± 8 and 400 ± 19 beat/min in vehicle and
EET-B-treated ANG II hypertensive rats, respectively (Figure 2B).
Urinary sodium excretion on day 14 was similar between EET-B
(2.2 ± 0.3 mmol/d) and vehicle (2.7 ± 0.4 mmol/d) treated ANG
II hypertensive rats. Moreover, at the end of the 14-day treatment
period there was no difference in the daily urine volume of ANG
II hypertensive rats treated with vehicle or EET-B (32 ± 4 vs.
29 ± 5 ml/day).
EET-B PRESERVES VASCULAR FUNCTION IN ANG II HYPERTENSION
In the present study, we determined the vasorelaxation response
of mesenteric resistance arteries to acetylcholine in vehicle and
EET-B-treated ANG II hypertensive rats at the end of 14-
day experimental protocol. Among the experimental groups,
there were no differences in the baseline arterial diameters
(288 ± 37 μm) or diameters after treatment with the thrombox-
ane mimetic U46619 (131 ± 14 μm). Relaxation of mesenteric
resistance arteries to acetylcholine was signiﬁcantly blunted in
ANG II hypertension compared to control SD rats (P < 0.05).
Mesenteric artery relaxation to 10 μM acetylcholine averaged
91 ± 2% in control SD and 49 ± 3% in ANG II hyperten-
sive rats (Figure 3). Interestingly, EET-B treatment markedly
improved the acetylcholine-mediated vasorelaxation in ANG II
hypertensive rats and the mesenteric artery response to 10 μM
acetylcholine averaged 78 ± 5% (P < 0.05). The mesenteric arter-
ies response to a nitric oxide donor sodium nitroprusside were
similar among the groups and averaged 93 ± 9%. These ﬁnd-
ings support the notion that mesenteric resistance artery vascular
function in ANG II hypertension is partially preserved by EET-B
treatment.
EET-B PROTECTS THE KIDNEY IN ANG II HYPERTENSION
As demonstrated in Figure 4, EET-B treatment protected the kid-
ney from ANG II hypertension-mediated damage. EET-B-treated
ANG II hypertensive rats demonstrated lower urinary excretions
of albumin and nephrin along with the presence of relatively nor-
mal renal histological features compared to vehicle-treated ANG
II hypertensive rats. Indeed, marked albuminuria and nephrin-
uria were found in ANG II hypertensive rats and EET-B treatment
protected the kidney as determined by 90% lower albuminuria
and 54% lower nephrinuria (P < 0.05; Figures 4A,B). Moreover,
in line with the marked albuminuria and nephrinuria in ANG II
hypertensive rats, histopathological study revealed mild tubular
proteinaceous cast formation, and these renal tubular casts were
fewer in EET-B-treated rats (P < 0.05; Figures 4C,D).
EET-B-TREATED ANG II HYPERTENSIVE RATS HAVE LOWER RENAL
INFLAMMATION
Angiotensin II hypertensive rats demonstrated renal inﬂammation
with 80% higher urinary excretion of MCP-1 compared to control
SD rats. Interestingly, EET-B-treated hypertensive rats had a55%
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FIGURE 3 | Effect of orally administered EET-B on mesenteric
resistance artery function in angiotensin II (ANG II) hypertension.
EET-B was administered at a dose of 10 mg/kg/day in the drinking water for
14 days. Mesenteric resistance artery basal diameter was not different
between experimental groups averaging 288 ± 37 μm (n = 24) under
control conditions and 131 ± 14 μm after administration of the
thromboxane mimetic U46619. Mesenteric resistance artery responses to
acetylcholine (0.001–10 μM) were determined. *P < 0.05 vs.
Sprague-Dailey (SD) + Vehicle and #P < 0.05 vs. ANG II + Vehicle. All data
presented as mean ± SEM, n = 8/group.
lower renal MCP-1 excretion (Figure 5A). In line with markedly
elevated MCP-1 excretion, we also observed a 60% increase in
kidney inﬁltration of macrophages in ANG II hypertensive rats.
EET-B-treated ANG II hypertensive rats had a 52% reduction in
renal macrophage inﬁltration compared to vehicle-treated ANG II
hypertensive rats (Figures 5B,C).
DISCUSSION
Epoxyeicosatrienoic acids have a number of cardiovascular actions
and play important roles in vascular and blood pressure con-
trol (Imig, 2010, 2012). Biological actions attributed to EETs are
expected to provide organ protection in a number of pathologies
including hypertension (Imig, 2010). In view of such important
biological actions of EETs, there has been a growing interest in
developing EET-based therapeutic strategies including the devel-
opment of inhibitors of sEH to prevent degradation of EETs.
Indeed, a large number of studies demonstrated beneﬁcial effects
of sEH inhibitors in a number of pathologies including hyperten-
sion (Imig et al., 2002, 2005; Zhao et al., 2004; Loch et al., 2007;
Manhiani et al., 2009; Imig, 2010, 2012). On the other hand,
sEH inhibitors have two drawbacks. First, they result in a gen-
eralized increase in EETs as well as other epoxides, and second,
their effectiveness depends on epoxygenase-mediated EET gen-
eration (Imig and Hammock, 2009). This second limitation is
important because renal and cardiovascular diseases are associ-
ated with impaired epoxygenase generation of EETs (Imig et al.,
2002; King et al., 2005; Imig and Hammock, 2009; Imig, 2010).
It is, therefore, likely that if epoxygenase-mediated EET genera-
tion is impaired, sEH inhibition will have a smaller or negligible
effect on EET levels in these pathological conditions. As such,
efforts have been made to develop stable EET agonist analogs with
several key features important for their stability and bioavailabil-
ity (Morisseau and Hammock, 2005; Falck et al., 2009). Several
of these EET analogs have demonstrated cardiovascular actions
in different experimental disease models (Imig et al., 2001, 2010;
Seubert et al., 2007; Sodhi et al., 2009; Hye Khan et al., 2013,
2014; Khan et al., 2013). In the present study, we investigated
anti-hypertensive, vascular, and kidney protective effects of one
such EET analog, EET-B, in ANG II hypertensive rats. EET-B
was designed by replacing acidic carboxyl group in carbon 1 of
EET pharmacophore with a heterocyclic surrogate. We demon-
strate that this EET analog attenuated the blood pressure elevation
in ANG II hypertension when administered orally in the drink-
ing water. Similar antihypertensive effects for EET analogs were
reported in earlier studies with metabolic syndrome mice, spon-
taneously hypertensive rats and also recently in rats with ANG II
hypertension (Sodhi et al., 2009; Imig et al., 2010; Hye Khan et al.,
2014).
The pathophysiology of ANG II hypertension is associated
changes in renal tubular sodium reabsorption and impaired vas-
cular function (Fyhrquist et al., 1995; Jennings et al., 2012; Hye
Khan et al., 2014). Vascular dysfunction constitutes an early inde-
pendent predictor of cardiovascular events in hypertension and
accordingly current therapeutic strategies are aimed at mitigat-
ing vascular dysfunction to reduce hypertension-related mortality
and morbidity (Puddu et al., 2000; Perticone et al., 2001). Indeed,
a larger reduction in the occurrence of cardiovascular events has
been demonstrated in hypertensive patients when vascular func-
tion is restored (Perticone et al., 2001). Reduced EET levels are
associated with vascular dysfunction in hypertension (Gao et al.,
2011). In an earlier study, we demonstrated enhanced affer-
ent arteriolar reactivity to ANG II in ANG II hypertension that
was reversed by administering a sEH inhibitor to increase EET
bioavailability (Imig et al., 2001). Moreover, a newly developed
orally active EET analog, EET-A improved mesenteric resis-
tance artery relaxation to acetylcholine in ANG II hypertension
(Hye Khan et al., 2014). In accordance with these previous ﬁnd-
ings, the current study demonstrates that treatment with EET-B
partially preserved acetylcholine-mediated dilation of mesen-
teric resistance arteries in ANG II hypertension. This vascular
effect of EET-B could be a direct effect of EET-B on the vas-
culature. Indeed, in an earlier study, we demonstrated that
EET-B caused marked vasodilation in pre-constricted mesenteric
resistance artery and at that EET-B vasodilation was abolished
in the presence of an EET antagonist, 14,15-epoxyeicosa-5(Z)-
enoic acid (14,15-EEZE; Hye Khan et al., 2013). Thus past and
current ﬁndings consistently demonstrate that sEH inhibitors
and EET analogs including EET-B improve vascular function in
hypertension.
In addition toANG II vasoconstrictor actions,ANG II increases
renal tubular sodium reabsorption which has been implicated in
the pathophysiology of ANG II hypertension. ANG II hyperten-
sion is associated with sodium retention caused by increasing
epithelial sodium channel (ENaC) activity and ENaC inhibition
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FIGURE 4 | Orally administered EET-B provides kidney protection in
angiotensin II (ANG II) hypertension. Urinary albumin (A), and nephrin
(B) excretion rates and formation of proteinacious cast in the kidney (C,D)
were determined in SD, ANG II hypertension, and ANG II hypertensive rats
treated with EET-B administered at a dose of 10 mg/kg/day in the drinking
water for 14 days. *P < 0.05 vs. normal SD rat; #P < 0.05 vs.
vehicle-treated ANG II hypertensive rat. All data presented as mean ± SEM,
n = 6/group.
FIGURE 5 | EET-B reduced renal inflammation in angiotensin II (ANG II)
hypertension. Urinary MCP-1excretion (A) and kidney macrophage inﬁltration
(B,C) were determined in SD, ANG II hypertension, and ANG II hypertensive
rats treated with EET-B administered at a dose of 10 mg/kg/day in the drinking
water for 14 days. *P < 0.05 vs. normal SD rat; #P < 0.05 vs. vehicle-treated
ANG II hypertensive rat. All data presented as mean ± SEM, n = 6/group.
attenuates ANG II hypertension (Beutler et al., 2003; Gonzalez
et al., 2011). Interestingly, EETs inhibit sodium reabsorption, and
this biological activity is implicated in their ability to lower blood
pressure (Imig, 2010, 2012). Indeed, EETs lower blood pressure
by reducing tubular Na+ reabsorption via ENaC inhibition (Wei
et al., 2004). ENaC inhibitory effects of EETs and EET analogs
including EET-A have been demonstrated using electrophysiolog-
ical measurements of the channel activity in immortalized mouse
cortical collecting duct principal (mpkCCDc14) cells (Pavlov et al.,
2011; Hye Khan et al., 2014). In contrast to these ﬁndings, using
a similar electrophysiological approach, we recently reported that
EET-B is a very weak ENaC inhibitor and did not affect basal
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Na+ transport in mpkCCDc14 cells (Hye Khan et al., 2014). In
accord with the electrophysiological ﬁndings, EET-B did not affect
sodium excretion in Dahl salt-sensitive hypertension (Hye Khan
et al., 2013). In the current study, EET-B did not alter urinary
sodium excretion as assessed on day 14 in ANG II hyperten-
sion. These data suggest that unlike EET-A, the anti-hypertensive
action of EET-B does not involve signiﬁcant changes in sodium
reabsorption and is more likely more dependent on its vascular
actions.
A pathophysiological consequence of hypertension-related
mortality and morbidity is end organ damage. Accordingly,
ANG II-dependent hypertension leads to kidney injury with
marked proteinuria, albuminuria and renal histopathological
changes (Jennings et al., 2012; Luft et al., 2012). Moreover,
ANG II activates immune cells and promotes inﬁltration of
such cells into organs including the kidney resulting in pro-
gressive renal injury (Park et al., 2009; Jennings et al., 2012).
In this regard, EET and EET analog could play important
roles in protecting from hypertension-mediated end organ dam-
age. Indeed, a number of studies have demonstrated strong
anti-inﬂammatory action of EETs and EET analogs that con-
tributes to end organ protection in a number of preclinical
models of human disease including hypertension (Olearczyk
et al., 2009; Elmarakby et al., 2011; Imig, 2012; Hye Khan et al.,
2013; Khan et al., 2013). In line with these previous ﬁndings,
the present study also demonstrates marked kidney protective
and anti-inﬂammatory effects of EET-B in ANG II hyperten-
sion along with a reduction in blood pressure. It is possible
that in ANG II hypertension, the reductions in kidney injury
and inﬂammation could be related to blood pressure reduction.
However, in several earlier studies we have demonstrated that
EET-B has blood pressure independent kidney protective and
anti-inﬂammatory actions. In Dahl salt sensitive rats we have
demonstrated that EET-B provides kidney protective as well as
anti-inﬂammatory effects without affecting the blood pressure
(Hye Khan et al., 2013). In another study with cisplatin-induced
nephrotoxicity, we also have demonstrated that orally adminis-
tered EET-B decreased renal injury and reduced renal mRNA
expression of interleukin-6, interleukin-1β, and tumor necro-
sis factor-α (TNF-α) along with a marked reduction of renal
TNF-α levels (Khan et al., 2013). Evidence for a direct anti-
inﬂammatory action of EET-B was demonstrated in human
umbilical vein endothelial cells where EET-B markedly attenu-
ated the TNF-α induced inﬂammatory response (Hye Khan et al.,
2013).Taken together, ﬁndings in earlier and the current study
indicate that EET-B reduces renal inﬂammation and provides
kidney protection in a number of pathologies including ANG II
hypertension.
In summary, in ANG II hypertension, the EET analog EET-B
reduces blood pressure elevation, partially preserves vascular
function, and provides kidney protection with marked anti-
inﬂammatory activity. These ﬁndings further demonstrate that
the cardiovascular and renal actions of EET analogs make them a
promising therapeutic approach for cardiovascular and renal dis-
eases. Future development of EET-B and other EET analogs is
required to determine their beneﬁt to combat cardiovascular and
renal diseases in humans.
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